Clinical Trials Logo

Hypertrophy clinical trials

View clinical trials related to Hypertrophy.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06397092 Completed - Anesthesia Clinical Trials

Anesthetic Management for TA-BSM in HOCM

Start date: April 1, 2022
Phase:
Study type: Observational

To retrospectively analyze the preoperative, intraoperative and postoperative anesthesia management of patients with hypertrophic cardiomyopathy undergoing TA-BSM in the investigators' hospital, and to provide clinical basis for the development of reasonable and standardized perioperative anesthesia program for these patients.

NCT ID: NCT06354413 Completed - Clinical trials for Coronary Artery Disease

Outcomes of Concomitant Bypass Surgery in Septal Myectomy

Start date: January 2009
Phase:
Study type: Observational

To investigate clinical characteristics and survival outcomes of patients with obstructive hypertrophic cardiomyopathy who underwent concomitant coronary artery bypass grafting during septal myectomy.

NCT ID: NCT06347081 Completed - Hypertrophic Scar Clinical Trials

Effect of Nd-YAG Laser on Hypertrophic Scar

Nd-YAG
Start date: May 1, 2022
Phase: N/A
Study type: Interventional

A hypertrophic scar is a serious health concern in the industrialized world. Two groups of patients were treated with standard medical care. The experimental group received additional laser therapy. scar assessment was measured immediately before treatment, after 3, and 7 months. T test for comparison before-treatment between the control and study groups. ANOVA with repeated measures test for comparison among other measures.

NCT ID: NCT06310083 Completed - Clinical trials for Turbinate; Hypertrophy Mucous Membrane

Endoscopic Submucosal Resection Turbinoplasty VS Turbinectomy

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The aim of our study is to compare endoscopic submucosal resection Turbinoplasty and partial inferior turbinectomy regarding clinical and radiological evaluation and its possible complications in the treatment of Chronic inferior turbinate hypertrophy.

NCT ID: NCT06190704 Completed - Clinical trials for Hypertrophic Cardiomyopathy Patients

Prognostic Significance of CMD Assessed by IMR in HCM Patients

caIMR-HCM
Start date: September 13, 2014
Phase:
Study type: Observational

The index of microcirculatory resistance (IMR) serves as an indicator of coronary microvascular dysfunction (CMD) with significant prognostic value in various clinical conditions. However, its impact on CMD in the hypertrophic cardiomyopathy (HCM), whether assessed invasively or non-invasively, is yet to be investigated. We assessed the prognostic importance of CMD using less invasive coronary angiography-derived IMR (caIMR) in HCM patients with nonobstructive epicardial coronary arteries.Patients with HCM who underwent invasive coronary angiography for suspected myocardial ischemia were included. Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR>25U, in line with prior research, and the primary study endpoint was major adverse cardiac events (MACE).

NCT ID: NCT06121869 Completed - Hypertrophy Clinical Trials

Dileucine and Resistance Training Adaptations

DTS
Start date: May 7, 2021
Phase: N/A
Study type: Interventional

This study seeks to compare the observed changes in resistance training adaptations after supplementation of isomolar amounts of leucine or dileucine in healthy resistance-trained men. This will provide a better understanding of supplementation with leucine versus dileucine over a 10-week period in regards to increasing muscular performance.

NCT ID: NCT06048562 Completed - Clinical trials for Hypertrophic Cardiomyopathy

Incidence of Hypertrophic Cardiomyopathy in Infants of Diabetic Mothers Attending in NICU at Assiut University Children Hospital During One Year

Start date: March 20, 2019
Phase: N/A
Study type: Interventional

To evaluate all full term infants of diabetic mother for the presence of hypertrophic cardiomyopathy who admitted in NICU at Assiut University Children Hospital and to follow up of these cases after 6 months for recovery.

NCT ID: NCT06020092 Completed - Clinical trials for Alveolar Ridge Enlargement

Histological Analysis of Osteogenic Potential of Biphasic Calcium Phosphate

Start date: July 31, 2021
Phase: Phase 4
Study type: Interventional

Bone healing after tooth extraction may be affected by defects in the buccal wall of the alveolus, such as fenestrations and dehiscences. Therefore, it is advisable to perform a surgical procedure such as guided bone regeneration after tooth extractions. Different biomaterials are used for this purpose. The aim of this study is to investigate the qualitative and quantitative histological changes in human biopsies taken after 6 months of healing of extraction sockets with buccal wall defects. For this purpose, the defects of 36 patients (18 per group) will be augmented with injectable biphasic calcium phosphate (I-BCP) or bovine xenograft (BX) after extraction. After six months of healing, bone biopsies will be taken and processed to the qualitative and quantitative histological analysis.

NCT ID: NCT05850026 Completed - Clinical trials for Mitral Regurgitation

Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!

Start date: October 5, 2019
Phase:
Study type: Observational

Septal myectomy is performed in selected cases to treat patients with hypertrophic obstructive cardiomyopathy (HOCM). The mechanism that causes obstruction involves both the outflow tract itself and the mitral apparatus, with the appearance of mitral regurgitation (MR) by SAM (Systolic Anterior Motion). When the interventricular septum is not particularly thick, isolated myectomy may not be sufficient to eliminate the SAM; in these cases the concomitant treatment of the mitral valve is considered. Different approaches have been proposed: mitral replacement with prosthesis, plication or lengthening of the anterior leaflet or the edge-to-edge (EE) technique. In addition, a small proportion of patients with HOCM may have MR from organic valve abnormalities, requiring specific treatment. Currently, there are few studies in the literature aimed at determining the role of EE in the context of HOCM; most of these studies are characterized by short follow-up or by the scarcity of echocardiographic data. The aim of the present study is to evaluate the long-term outcomes of EE associated with septal myectomy in patients with CMIO, both from a clinical point of view and by reporting echocardiographic data.

NCT ID: NCT05848505 Completed - Clinical trials for Tonsillar Hypertrophy

Opioid-sparing Effect of Intranasal Dexmedetomidine

Start date: February 25, 2022
Phase: N/A
Study type: Interventional

Background: Management of postoperative pain in paediatric patients undergoing tonsillectomy remains a challenge that faces anesthesiologists in their daily practice. High dose of opioids are usually necessary and are responsible for side effects like nausea, vomiting, constipation, delayed hospital discharge and more importantly respiratory depression and sleep apnea. Dexmedetomidine is a selective alpha two agonist that has an analgesic and anxiolytic effect with minimal effects on respiratory drive. Goal of the study: The aim of this study is to assess the opioid sparing effect of preoperative intranasal dexmedetomidine as part of multimodal analgesia in the paediatric population undergoing tonsillectomy. Methods: This will be a prospective, randomised, controlled, double blinded clinical trial with 50 participants who will be randomised between two groups: dexmedetomidine group and control group. The dexmedetomidine group will receive intranasal dexmedetomidine in the preoperative holding area while the other group will receive the placebo. The primary endpoint will be the total fentanyl consumption in the perioperative period. Additionally, we will look at postoperative pain scores at 10, 30 and 60 minutes after recovery as well as the time to first opioid rescue analgesic and agitation scores as secondary endpoints. Blood pressure and hart rate will also be recorded throughout the study period.